Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops new therapies to address unmet medical needs for the treatment of cancer. The company's lead product candidate is VIP152 that is in Phase I clinical trials to treat solid tumors. Its preclinical stage product candidates include VIP217 for solid tumors; VIP236 to treat multiple solid tumors; VIP943 for the treatment of leukemia and myelodysplastic syndrome; and VIP924 for treating B-cell malignancies. Vincerx Pharma, Inc. was founded in 2019 is based in Palo Alto, California.
IPO Year: 2025
Exchange: NASDAQ
Website: vincerx.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/14/2022 | $25.00 | Buy | HC Wainwright & Co. |
| 12/23/2021 | $25.00 | Overweight | Cantor Fitzgerald |
| 11/1/2021 | $24.00 | Outperform | SVB Leerink |
| 9/13/2021 | $30.00 | Buy | Laidlaw |
| 8/25/2021 | $26.00 | Buy | B. Riley Securities |
| 8/13/2021 | $33.00 → $30.00 | Buy | Chardan Capital |
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
3 - Vincerx Pharma, Inc. (0001796129) (Issuer)
4 - Vincerx Pharma, Inc. (0001796129) (Issuer)
4 - Vincerx Pharma, Inc. (0001796129) (Issuer)
4 - Vincerx Pharma, Inc. (0001796129) (Issuer)
4 - Vincerx Pharma, Inc. (0001796129) (Issuer)
4 - Vincerx Pharma, Inc. (0001796129) (Issuer)
4 - Vincerx Pharma, Inc. (0001796129) (Issuer)
4 - Vincerx Pharma, Inc. (0001796129) (Issuer)
4 - Vincerx Pharma, Inc. (0001796129) (Issuer)
4 - Vincerx Pharma, Inc. (0001796129) (Issuer)
SCHEDULE 13G/A - Vincerx Pharma, Inc. (0001796129) (Subject)
DEFA14A - Vincerx Pharma, Inc. (0001796129) (Filer)
DEFA14A - Vincerx Pharma, Inc. (0001796129) (Filer)
8-K - Vincerx Pharma, Inc. (0001796129) (Filer)
DEFA14A - Vincerx Pharma, Inc. (0001796129) (Filer)
DEFA14A - Vincerx Pharma, Inc. (0001796129) (Filer)
10-Q - Vincerx Pharma, Inc. (0001796129) (Filer)
SCHEDULE 13G/A - Vincerx Pharma, Inc. (0001796129) (Subject)
DEF 14A - Vincerx Pharma, Inc. (0001796129) (Filer)
EFFECT - Vincerx Pharma, Inc. (0001796129) (Filer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
HC Wainwright & Co. initiated coverage of Vincerx Pharma with a rating of Buy and set a new price target of $25.00
Cantor Fitzgerald initiated coverage of Vincerx Pharma with a rating of Overweight and set a new price target of $25.00
SVB Leerink initiated coverage of Vincerx Pharma with a rating of Outperform and set a new price target of $24.00
Laidlaw initiated coverage of Vincerx with a rating of Buy and set a new price target of $30.00
B. Riley Securities initiated coverage of Vincerx Pharma with a rating of Buy and set a new price target of $26.00
Chardan Capital reiterated coverage of Vincerx Pharma with a rating of Buy and set a new price target of $30.00 from $33.00 previously
Fastest customizable press release news feed in the world
Revised Potential Distribution Range of $0.03 to $0.07 per sharebased on current estimates and assumptions Failure to approve Dissolution Proposal on a timely basis will result in continued operating costs and further reduce or eliminate any potential distributions to stockholders SAN MATEO, Calif., July 16, 2025 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (OTC:VINC) today announced that the re-convened Special Meeting of Stockholders to consider a proposal to approve the liquidation and dissolution of Vincerx (the "Dissolution Proposal"), which was originally scheduled for earlier today, has again been adjourned, this time until 10:00 a.m., Pacific time, on August 27, 2025 via li
Potential Distribution Range of $0.04 to $0.08 per share of outstanding stock based on current estimates and assumptions, including timely approval of Distribution Proposal Failure to approve Dissolution Proposal will reduce or eliminate any potential distributions to stockholders SAN MATEO, Calif., July 07, 2025 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (OTC:VINC) today announced updated information regarding the Special Meeting of Stockholders of the Company (the "Special Meeting") to consider the proposal to approve the dissolution and liquidation of the Company pursuant to the Plan of Liquidation and Dissolution (the "Dissolution Proposal"). The Special Meeting was adjourned to 10:0
SAN MATEO, Calif., June 18, 2025 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (OTC:VINC) today announced that the Special Meeting of Stockholders to consider a proposal to approve the liquidation and dissolution of Vincerx (the "Dissolution Proposal"), which was originally scheduled for earlier today, has been adjourned until 10:00 a.m., Pacific time, on July 16, 2025 via live audio webcast at www.virtualshareholdermeeting.com/VINC2025SM2. The adjournment will allow Vincerx more time to solicit the votes needed to approve the Dissolution Proposal. Vincerx is urging ALL stockholders to vote IMMEDIATELY FOR the Dissolution Proposal. Vincerx's board of directors unanimously recommends that stoc
Vincerx common stock suspended by Nasdaq inadvertently; will resume trading at the open of business on April 21, 2025 Trading to be permanently suspended by Nasdaq at the open of business on April 23, 2025 SAN MATEO, Calif., April 17, 2025 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (NASDAQ:VINC) today announced its intention to file a Form 25 Notification of Delisting with the Securities and Exchange Commission ("SEC") on or about April 28, 2025, which will remove Vincerx's common stock from listing and registration on The Nasdaq Stock Market ("Nasdaq"). On April 14, 2025, Vincerx received written notice from Nasdaq that it was not in compliance with Nasdaq Listing Rule 5550(a)(2) because
SAN MATEO, Calif., April 08, 2025 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (NASDAQ:VINC) today announced that it has terminated the previously announced non-binding Letter of Intent (LOI) with Global Digital Holdings Inc., conducting business as QumulusAI, regarding a potential merger. Following this decision, the Company's board of directors has authorized management to initiate wind-down activities and continue exploring monetization of assets and out-licensing opportunities. "I want to express our deepest gratitude to the investigators, patients, employees, and partners who have supported Vincerx's mission," said Raquel Izumi, Ph.D., Acting Chief Executive Officer of Vincerx. "Your co
SAN MATEO, Calif., March 18, 2025 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (NASDAQ:VINC) today announced that it has entered into a non-binding letter of intent ("LOI") with Global Digital Holdings Inc., conducting business as QumulusAI, a privately-held, high-performance computing infrastructure company for artificial intelligence (AI), relating to a business combination between Vincerx and QumulusAI. The contemplated transaction would result in QumulusAI becoming a publicly traded company through a reverse triangular merger with Vincerx. Under the proposed terms, a subsidiary of Vincerx would merge into QumulusAI, with QumulusAI stockholders receiving shares of Vincerx common stock.
SAN MATEO, Calif., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (NASDAQ:VINC) today announced that the previously signed binding Term Sheet between Vincerx, Oqory, Inc., and Vivasor, Inc. for a reverse merger transaction has been terminated. As a result, the board of directors will reassess the Company's strategic alternatives, including out-licensing, merger and acquisition opportunities (including reverse mergers), the sale of assets and technologies, and winding down operations, among other potential transactions. As of February 26, 2025, the Company had approximately $3.9 million in cash. The Company's cash runway is expected to extend through late Q2 2025. Forward-L
SAN MATEO, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (NASDAQ:VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, and Oqory, Inc., a private biopharmaceutical company dedicated to developing next-generation antibody drug conjugates (ADCs) for the treatment of cancer, today highlighted Phase 1a/1b data for Oqory's anti-TROP2 ADC, OQY-3258, for patients with solid tumors. The companies also provided insights into their proposed strategic merger, which aims to advance OQY-3258 into global Phase 3 trials and build a differentiated ADC pipeline by leveraging their combined expertise.
SAN MATEO, Calif., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (NASDAQ:VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced that its board of directors approved a 1-for-20 reverse stock split of its issued shares of common stock, which will be effective as of January 27, 2025 at 4:01 p.m., Eastern Time. Vincerx's common stock will continue trading on The Nasdaq Stock Market ("Nasdaq") under the existing symbol (VINC) and will begin trading on a split-adjusted basis when the market opens on January 28, 2025 with a new CUSIP number. The reverse stock split was approved by Vinc
PALO ALTO, Calif., Dec. 27, 2024 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (NASDAQ:VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced that it has entered into a binding term sheet for a proposed merger with Oqory, Inc., a privately-held, clinical-stage company developing ADCs for the treatment of multiple oncology indications. Upon completion of the proposed merger, Oqory, Inc. will merge with Vincerx Pharma, Inc. Post-closing, Oqory equity holders are expected to own approximately 95% of the combined entity, while Vincerx equity holders will hold about 5%. The transaction
This live feed shows all institutional transactions in real time.
SC 13G - Vincerx Pharma, Inc. (0001796129) (Subject)
SC 13G/A - Vincerx Pharma, Inc. (0001796129) (Subject)
SC 13G/A - Vincerx Pharma, Inc. (0001796129) (Subject)
SC 13G - Vincerx Pharma, Inc. (0001796129) (Subject)
SC 13G/A - Vincerx Pharma, Inc. (0001796129) (Subject)
SC 13G/A - Vincerx Pharma, Inc. (0001796129) (Subject)
SC 13G - Vincerx Pharma, Inc. (0001796129) (Subject)
SC 13G/A - Vincerx Pharma, Inc. (0001796129) (Subject)
SC 13G/A - Vincerx Pharma, Inc. (0001796129) (Subject)
SC 13G - Vincerx Pharma, Inc. (0001796129) (Subject)